Compare Elanco Animal Health Incorporated Common Stock (ELAN) vs Genworth Financial Inc Common Stock (GNW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elanco Animal Health Incorporated Common Stock vs Genworth Financial Inc Common Stock — how do they compare? Elanco Animal Health Incorporated Common Stock trades at $22.7 (market cap $11.27B), while Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.33B). The key difference: Elanco Animal Health Incorporated Common Stock is far larger — about 3.4× Genworth Financial Inc Common Stock's market cap, and Elanco Animal Health Incorporated Common Stock is more actively traded (4,942,915 versus 3,324,561). Which is the better fit depends on your goals — on Pluang, investors hold Elanco Animal Health Incorporated Common Stock for 6 Days and Genworth Financial Inc Common Stock for 0 Days on average.
| ELAN | GNW | |
|---|---|---|
Market Cap | $11.27B | $3.33B |
Volume | 4,942,915 | 3,324,561 |
Sector | Health | Financials |
52-Week High | $26.84 | $10.60 |
52-Week Low | $19.80 | $7.94 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.65B | $2.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELAN trades at $22.41, down 0.66% today, with a bearish technical signal from moving averages. The company reported a net loss of $232 million in 2025, though revenue grew to $4.72 billion. Recent earnings beats and a 71% analyst buy rating reflect optimism around new product launches like Zenrelia and deleveraging plans discussed at recent conferences.
The outlook hinges on execution of growth initiatives to achieve profitability. Upside exists if new products gain market share as projected, but risks include persistent losses, competitive pressures, and high debt. The consensus price target of $28.00 suggests 25% potential upside from current levels.
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Elanco Animal Health Incorporated Common Stock
Elanco develops medicines, vaccines, and other health products for pets and livestock. Its products address prevention and treatment of animal diseases.
Read more on ELAN →About Genworth Financial Inc Common Stock
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →
